# US 2015/0104439 A1 · Pharmaceutical removal of neuronal extensions from a degenerating disc

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104439 A1
- Document ID: US20150104439A1
- Status: Published application
- Kind: A1
- Application number: 14/577,307
- Filed: 2014-12-19
- Published: 2015-04-16
- Earliest claimed: 2006-04-28
- Assignees: Warsaw Orthopedic, Inc.
- Applicants: Warsaw Orthopedic, Inc.
- Inventors: Josee Roy; Susan J. Drapeau; Jeffrey C. Marx
- Web page: https://patentgrep.com/patent/US20150104439A1

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 31/11: Aldehydes
- A61K 31/125: Camphor; Nuclear substituted derivatives thereof
- A61K 31/225: Polycarboxylic acids
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/65: Tetracyclines
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 33/02: Ammonia; Compounds thereof
- A61K 36/31: Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61K 38/168: {from plants}
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.

## Claims

### Claim 1

A method for treating back or neck pain with or without radiculopathy comprising providing an effective amount of a therapeutic agent to a disc region comprising a disc, the therapeutic agent adapted to disrupt a neuronal element in the disc region.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disc is a degenerated disc.

### Claim 3 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to destroy, force retraction or block further growth of the neuronal element innervating the disc region.

### Claim 4 (depends on 3)

The method of claim 3, wherein the therapeutic agent modulates at least one growth factor, or modulates the response of the neuronal element to at least one growth factor.

### Claim 5 (depends on 4)

The method of claim 4, wherein the growth factor is selected from a set consisting of nerve growth factor, brain-derived growth factor, glial-derived growth factor, neurotrophin-3, neurotrophin-4, insulin-growth factor, fibroblast growth factor and leukemia inhibitory factor.

### Claim 6 (depends on 3)

The method of claim 3, wherein the therapeutic agent modulates at least one extra-cellular matrix component, or modulates•the response of the neuronal element to the at least one extra-cellular matrix component.

### Claim 7 (depends on 6)

The method of claim 6, wherein the extra-cellular matrix component is selected from a set consisting of chondroitin sulfate proteglycans, netrins semaphorins and myelin/oligodendrocyte growth inhibitors.

### Claim 8 (depends on 7)

The method of claim 7, wherein the myelin/oligodendrocyte growth inhibitors are selected from a set consisting of Nogo, MAG and OMgp.

### Claim 9 (depends on 6)

The method of claim 6, wherein the extra-cellular matrix component is a cell adhesion molecule.

### Claim 10 (depends on 9)

The method of claim 9 wherein the cell adhesion molecule is selected from a set consisting of NCAM, N-cadherins and integrins.

### Claim 11 (depends on 3)

The method of claim 3, wherein the therapeutic agent modulates a cytoskeletal component of the neuronal elements.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cytoskeletal component is selected from a set consisting of actins, tubulins and neurofilaments.

### Claim 13 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to desensitize the neuronal element innervating the disc region.

### Claim 14 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to modulate a receptor or a molecule that binds to a receptor of the neuronal element innervating the disc region.

### Claim 15 (depends on 14)

The method of claim 14, wherein the therapeutic agent is adapted to modulate neuronal receptors selected from a set consisting of nociceptors, vanilloid, adrenergic, cholinergic, glutamate, GABA, serotonine, somatostatin opioids, ATP, Na+, K+, Ca2+, cannabinoids, Substance P and neuropeptide receptors.

### Claim 16 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to block the modulation of neuronal elements by a pro-inflammatory molecule.

### Claim 17 (depends on 16)

The method of claim 16, wherein the pro-inflammatory molecule is selected from a set consisting of cytokines, chemokines, neuropeptides, bradykinin, histamines and prostaglandins.

### Claim 18 (depends on 1)

The method of claim 1, wherein the therapeutic agent is adapted to modulate glial cells.

### Claim 19 (depends on 18)

The method of claim 18, wherein the therapeutic agent is toxic to the glial cells.

### Claim 20 (depends on 1)

The method of claim 1, wherein the therapeutic agent comprises at least one active ingredient selected from a set consisting of natural neurotoxins; neurotoxins comprising ammonia or cyanide; bisbenzimide; trypan blue; brilliant blue; methylene blue; indocyanine green; ruthenium red; quinoline yellow; saporin; Rho kinase activators; camphor; menthol; piperine; mustard oil; eugenol; curcumin; 8-Methyl-N-vanillyl-trans-6-nonenamide (Capsaicin); Z-Capsaicin; Gingerol; Zingerone; 8-Methyl-N-vanillylnonanamide (Dihydrocapsaicin); 6,7-Deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)-daphnetoxin, 20-(4-hydroxy-5-iodo-3-methoxybenzeneacetate) (5′-Iodoresiniferatoxin); (+)-Isovelleral; N-Vannilyloleoylamide (Olvanil); Phorbol 12,13-dinonanoate 20-homovanillate; Resiniferatoxin; N-(3-Methoxyphenyl)-4 chlorocinnamide (SB-366791); 6,7-Deepoxy-6,7-didehydro-5-deoxy-21-dephenyl-21-(phenylmethyl)-20-(4-hydroxybenzeneacetate)daphnetoxin (Tinyatoxin); capsaicin synthetics; capsaicin derivatives; botulinum toxin; anti-convulsants; anesthetics; analgesics; opioids; cannabinoids; N-[2-(4-Chlorophenyl)ethyl]-1,3,4,5-tetrahydro-7,8-dihydroxy-2H-2-benzazepine-2-carbothioamide (Capsazepine); [N-(4-Hydroxy-3-methoxyphenyl)methyl]-5Z,8Z,11Z,14Z-eicosatetraenamide] (Arvanil); N-(3-Methoxyphenyl)-4-chlorocinnamide (SB-366791); 5′-iodoresiniferatoxin; steroids; nonsteroidal anti-inflammatory compounds; COX inhibitors; modulators of TNF-alpha or IL-1 cytokines or receptors; NFkB modulators; minocyclin and fluorocitrate (Capsazepine); [N-(4-Hydroxy-3-methoxyphenyl)methyl]-5Z,8Z,11Z,14Z-eicosatetraenamide] (Arvanil); N-(3-Methoxyphenyl)-4-chlorocinnamide (SB-366791);
5′-iodoresiniferatoxin; steroids; nonsteroidal anti-inflammatory compounds; COX inhibitors; modulators of TNF-alpha or IL-1 cytokines or receptors; NFkB modulators; minocyclin and fluorocitrate.
